Subscribe
sanofi
Monticello / Shutterstock
6 June 2023FeaturesBig PharmaMuireann Bolger

Sanofi v Amgen antibody case lands front of queue at UPC

The  Unified Patent Court (UPC) may be less than a week old but it is already set to be the latest stage for the long-running dispute between Sanofi and Amgen concerning antibody patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
UPC announces hearing details for Edwards Lifesciences
31 August 2023   Edwards Lifesciences files application for provisional measures at UPC | Hearing details adds to existing listed by the court for 10x Genomics versus NanoString.
Big Pharma
UPC confirms dates for 10x Genomics hearings
22 August 2023   UPC announces public hearings at Munich court | Proceedings relate to the dispute over patents covering the in-situ detection of analytes.
Big Pharma
UPC: life sciences lead the momentum at new court
15 August 2023   Are we now seeing the power posed by the court as a litigation forum, asks Antje Brambrink of Finnegan.


Editor's picks

Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025

Editor's picks

Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025

More on this story

Big Pharma
UPC announces hearing details for Edwards Lifesciences
31 August 2023   Edwards Lifesciences files application for provisional measures at UPC | Hearing details adds to existing listed by the court for 10x Genomics versus NanoString.
Big Pharma
UPC confirms dates for 10x Genomics hearings
22 August 2023   UPC announces public hearings at Munich court | Proceedings relate to the dispute over patents covering the in-situ detection of analytes.
Big Pharma
UPC: life sciences lead the momentum at new court
15 August 2023   Are we now seeing the power posed by the court as a litigation forum, asks Antje Brambrink of Finnegan.

More on this story

Big Pharma
UPC announces hearing details for Edwards Lifesciences
31 August 2023   Edwards Lifesciences files application for provisional measures at UPC | Hearing details adds to existing listed by the court for 10x Genomics versus NanoString.
Big Pharma
UPC confirms dates for 10x Genomics hearings
22 August 2023   UPC announces public hearings at Munich court | Proceedings relate to the dispute over patents covering the in-situ detection of analytes.
Big Pharma
UPC: life sciences lead the momentum at new court
15 August 2023   Are we now seeing the power posed by the court as a litigation forum, asks Antje Brambrink of Finnegan.

More features

Fed Circ: Generic doesn’t infringe Metacel MS drug
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
In vivo cell therapy: A world beyond ex vivo engineering
Resilience and the power of brands: Elisabeth Stewart Bradley on 9/11, inclusion and the INTA presidency
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug